Möchten Sie immer auf dem neuesten Stand bleiben?

Oslo, 16 April 2018: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2017. The annual accounts and annual report for the financial year 2017 are...

Oslo, 16 April 2018: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 9 May 2018 at 17:00 hours (CET). The...

Oslo, Norway, 27 February 2018: Photocure ASA (OSE:PHO), today reported a revenue growth of 27% for the important U.S. market in the fourth quarter of 2017, contributing to Hexvix®/Cysview®...

Photocure will present its fourth quarter and full year 2017 report on Tuesday 27 February 2018 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives...

Oslo, Norway, February 16, 2018 Photocure ASA (OSE: PHO), announced today that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) to extend the...

Oslo, Norway, December 13, 2017 - Photocure ASA (OSE: PHO) announces today that the company will present at the DNB Nordic Healthcare Conference on 14th of December 2017 in Oslo, Norway. Presenter...

Oslo, Norway, December 8, 2017: Photocure ASA (Photocure, PHO: OSE), today announced that the official Journal of the American Urologic Association (AUA), the Journal of Urology, published the...

Oslo, Norway, December 5, 2017 - Photocure ASA (OSE: PHO) announced today that the company will present at the Carnegie Nordic Healthcare Day, New York, on 5 December 2017. Presenter will be Ambaw...

Oslo, Norway, December 1, 2017 Photocure ASA (OSE: PHO) announced today that more detailed data from the Phase 3 study data was presented at the prestigious Society of Urologic Oncology, Annual...

A poster demonstrating the clinical and cost impact of Cevira® was presented at the ISPOR European congress in Glasgow, Scotland, November 4-8, 2017. The budget impact model from a US payer...